Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study

被引:74
作者
Kavanaugh, Arthur [1 ,2 ]
McInnes, Iain B. [3 ,4 ,5 ]
Mease, Philip J. [6 ,7 ]
Hall, Stephen [8 ]
Chinoy, Hector [10 ]
Kivitz, Alan J. [9 ]
Wang, Zailong [11 ]
Mpofu, Shephard [11 ]
机构
[1] Univ Calif San Diego, Sch Med, Med Clin, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, Ctr Innovat Therapy, La Jolla, CA 92093 USA
[3] Univ Glasgow, Expt Med Immunol, Glasgow, Lanark, Scotland
[4] Univ Glasgow, Med, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Immunol Infect & Inflammat, Inst Sch Med, Glasgow, Lanark, Scotland
[6] Swedish Med Ctr, Rheumatol Clin Res Div, Seattle, WA USA
[7] Univ Washington, Sch Med, Seattle, WA USA
[8] Monash Univ, Melbourne, Vic, Australia
[9] Altoona Ctr Clin Res, Duncansville, PA USA
[10] Univ Manchester, NIHR Manchester Musculoskeletal Biomed Res Unit, Cent Manchester Univ Hosp NHS Fdn Trust, Rheumatol, Manchester, Lancs, England
[11] Novartis, Hyderabad, Telangana, India
关键词
SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; PSORIATIC ARTHRITIS; BIOLOGICS; INTERLEUKIN; 17A; SPONDYLOARTHRITIS; THERAPY; TRIAL;
D O I
10.3899/jrheum.160275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine the effect of prior tumor necrosis factor inhibitor (TNFi) therapy on secukinumab efficacy in psoriatic arthritis (PsA). Methods. Patients were randomized to secukinumab 300 mg, 150 mg, 75 mg, or placebo. Results. American College of Rheumatology 20 responses at Week 24 with secukinumab 300 mg, 150 mg, 75 mg, and placebo were 58.2%, 63.5%, 36.9%, and 15.9% in TNFi-naive (n = 258), and 45.5%, 29.7%, 14.7%, and 14.3% in TNFi-exposed patients (n = 139), respectively. Week 52 responses with secukinumab 300 mg, 150 mg, and 75 mg were 68.7%, 79.4%, and 58.5% in TNFi-naive, and 54.5%, 37.8%, and 35.3% in TNFi-exposed patients, respectively. Conclusion. Secukinumab was efficacious in TNFi-naive and TNFi-exposed patients with PsA, with greatest improvements in TNFi-naive patients.
引用
收藏
页码:1713 / 1717
页数:5
相关论文
共 8 条
[1]   Adalimumab for long-term treatment of psoriatic arthritis - Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial [J].
Gladman, Dafna D. ;
Mease, Philip J. ;
Ritchlin, Christopher T. ;
Choy, Ernest H. S. ;
Sharp, John T. ;
Ory, Peter A. ;
Perdok, Renee J. ;
Sasso, Eric H. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (02) :476-488
[2]   Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry [J].
Glintborg, Bente ;
Ostergaard, Mikkel ;
Krogh, Niels Steen ;
Andersen, Martin Dehn ;
Tarp, Ulrik ;
Loft, Anne Gitte ;
Lindegaard, Hanne M. ;
Holland-Fischer, Mette ;
Nordin, Henrik ;
Jensen, Dorte Vendelbo ;
Olsen, Christian Holkmann ;
Hetland, Merete Lund .
ARTHRITIS AND RHEUMATISM, 2013, 65 (05) :1213-1223
[3]   Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
McInnes, Iain B. ;
Mease, Philip J. ;
Kirkham, Bruce ;
Kavanaugh, Arthur ;
Ritchlin, Christopher T. ;
Rahman, Proton ;
Van der Heijde, Desiree ;
Landewe, Robert ;
Conaghan, Philip G. ;
Gottlieb, Alice B. ;
Richards, Hanno ;
Pricop, Luminita ;
Ligozio, Gregory ;
Patekar, Manmath ;
Mpofu, Shephard .
LANCET, 2015, 386 (9999) :1137-1146
[4]  
Mease P, 2015, CLIN EXP RHEUMATOL, V33, pS104
[5]   Psoriatic arthritis and spondyloarthritis assessment and management update [J].
Mease, Philip .
CURRENT OPINION IN RHEUMATOLOGY, 2013, 25 (03) :287-296
[6]  
Mease PJ, 2006, J RHEUMATOL, V33, P712
[7]   Effect of IL-17A blockade with secukinumab in autoimmune diseases [J].
Patel, Dhavalkumar D. ;
Lee, David M. ;
Kolbinger, Frank ;
Antoni, Christian .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 :116-123
[8]   Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis [J].
Raychaudhuri, Smriti K. ;
Saxena, Ankit ;
Raychaudhuri, Siba P. .
CLINICAL RHEUMATOLOGY, 2015, 34 (06) :1019-1023